Two Indian firms seeking to set right compliance deviations at their sites appear to have made notable gains. Biocon Ltd. and Dr. Reddy's Laboratories Ltd. have received establishment inspection reports [EIRs] from the US Food and Drug Administration at their sites in Bangalore and Duvvada respectively in India.
The EIR for the Biocon’s aseptic drug product facility states that the inspection stands closed, though the FDA has classified...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?